Molecular and Epigenetic Regulation of Cardiovascular Function

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cells of the Cardiovascular System".

Deadline for manuscript submissions: closed (20 May 2022) | Viewed by 6037

Special Issue Editor


E-Mail Website
Guest Editor
Center for Perinatal Biology, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92354, USA
Interests: fetal programming of neuro- and cardio-vascular disease; cardiovascular adaptation to pregnancy and maternal stress; epigenetic regulation of cardiovascular function; fetal brain and cardiovascular development

Special Issue Information

Dear Colleagues,

Epigenetic regulation/modification relates to the stable and heritable patterns of gene expression that do not involve changes in the DNA sequence. Unlike genetic regulation, which is extremely stable and irreversible, epigenetic modifications mark the effects of early environmental events and ensure sustained and reversible responses to transient stimuli, which result in modified gene expression patterns and phenotypes later in life. Growing evidence suggests that the epigenetic regulation of gene expression patterns plays an important role in the developmental programming of cardiovascular disease. However, the cell and molecular epigenetic mechanisms underlying environmental stress-induced cardiovascular disease are still not fully understood.

For this Special Issue, we invite scientific investigators to contribute original research articles, reviews, or shorter “Perspective” articles on all aspects related to the “Molecular Epigenetic Regulation of Cardiovascular Function”. Suggested potential topics include, but are not limited to, the following: maternal stress and fetal programming of cardiovascular dysfunctional phenotypes in late life; epigenetic regulatory role of DNA methylation, RNA methylation, miRNA regulation, and histone modification in the development of cardiovascular dysfunction; identification of the epigenetic biomarkers contributing to cardiovascular disease.

Dr. Daliao Xiao
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epigenetic regulation
  • maternal environmental stress exposure
  • fetal programming of cardiovascular dysfunction
  • epigenetic mechanisms/biomarkers

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 4218 KiB  
Review
Emerging Roles and Mechanism of m6A Methylation in Cardiometabolic Diseases
by Zujie Xu, Binbin Lv, Ying Qin and Bing Zhang
Cells 2022, 11(7), 1101; https://doi.org/10.3390/cells11071101 - 24 Mar 2022
Cited by 24 | Viewed by 5698
Abstract
Cardiometabolic diseases (CMDs) are currently the leading cause of death and disability worldwide, and their underlying regulatory mechanisms remain largely unknown. N6-methyladenosine (m6A) methylation, the most common and abundant epigenetic modification of eukaryotic mRNA, is regulated by m6A methyltransferase, demethylase, and the m6A [...] Read more.
Cardiometabolic diseases (CMDs) are currently the leading cause of death and disability worldwide, and their underlying regulatory mechanisms remain largely unknown. N6-methyladenosine (m6A) methylation, the most common and abundant epigenetic modification of eukaryotic mRNA, is regulated by m6A methyltransferase, demethylase, and the m6A binding protein, which affect the transcription, cleavage, translation, and degradation of target mRNA. m6A methylation plays a vital role in the physiological and pathological processes of CMDs. In this review, we summarize the role played by m6A methylation in CMDs, including obesity, hypertension, pulmonary hypertension, ischemic heart disease, myocardial hypertrophy, heart failure, and atherosclerosis. We also describe mechanisms that potentially involve the participation of m6A methylation, such as those driving calcium homeostasis, circadian rhythm, lipid metabolism, autophagy, macrophage response, and inflammation. m6A methylation and its regulators are expected to be targets for the treatment of CMDs. Full article
(This article belongs to the Special Issue Molecular and Epigenetic Regulation of Cardiovascular Function)
Show Figures

Figure 1

Back to TopTop